Amylyx Pharmaceuticals (AMLX) Assets Average (2022 - 2026)
Amylyx Pharmaceuticals (AMLX) posted quarterly Assets Average of $313.1 million for Q1 2026, up 51.52% year-over-year from $206.7 million in Q1 2025, and down 9.94% quarter-over-quarter from $347.7 million in Q4 2025.
Amylyx Pharmaceuticals (AMLX) Assets Average (2022 - 2026) Analysis & Trends
Amylyx Pharmaceuticals' Assets Average history runs 5 years deep, the most recent figure standing at $313.1 million for Q1 2026.
- In Q1 2026, Assets Average rose 51.52% year-over-year to $313.1 million; the TTM figure through Mar 2026 stood at $313.1 million (up 51.52% YoY), while the FY2025 annual figure was $263.1 million, down 25.99% from the prior year.
- Assets Average for Q1 2026 stood at $313.1 million, down from $347.7 million in the prior quarter.
- The five-year high for Assets Average was $492.0 million in Q4 2023, with the low at $190.0 million in Q1 2022.
- The 5-year median for Assets Average is $291.4 million (2024), against an average of $318.9 million.
- The sharpest annual moves came in 2023 and 2025: Assets Average soared 126.26% in 2023, then sank 55.79% in 2025.
- Amylyx Pharmaceuticals' Assets Average stood at $286.4 million in 2022, then jumped by 71.77% to $492.0 million in 2023, then sank by 54.84% to $222.2 million in 2024, then soared by 56.5% to $347.7 million in 2025, then retreated by 9.94% to $313.1 million in 2026.
- Business Quant data shows AMLX's Assets Average at $313.1 million in Q1 2026, $347.7 million in Q4 2025, and $278.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.65 Bn | 42.68 Bn | - | 43.72 Bn |
| 2 | Teva Pharmaceutical Industries | 43.09 Bn | 39.44 Bn | 2.15 Bn | 39.95 Bn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 15.12 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 98.59 Bn |
| 5 | United Therapeutics | 22.11 Bn | 19.45 Bn | 683.80 Mn | 6.97 Bn |
| 6 | Viatris | 18.77 Bn | 17.88 Bn | 1.46 Bn | 35.94 Bn |
| 7 | Neurocrine Biosciences | 15.62 Bn | 15.23 Bn | 935.80 Mn | 5.13 Bn |
| 8 | Elanco Animal Health | 12.07 Bn | 11.54 Bn | 798.00 Mn | 13.39 Bn |
| 9 | Dr Reddys Laboratories | 10.09 Bn | 9.93 Bn | - | 5.97 Bn |
| 10 | Amylyx Pharmaceuticals | 4.36 Bn | 4.36 Bn | - | 279.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 279.08 Mn |
| Mar 31, 2026 | 313.12 Mn |
| Dec 31, 2025 | 347.69 Mn |
| Sep 30, 2025 | 278.67 Mn |
| Jun 30, 2025 | 207.14 Mn |
| Mar 31, 2025 | 206.66 Mn |
| Dec 31, 2024 | 222.17 Mn |
| Sep 30, 2024 | 291.44 Mn |
| Jun 30, 2024 | 374.81 Mn |
| Mar 31, 2024 | 467.46 Mn |
| Dec 31, 2023 | 492.02 Mn |
| Sep 30, 2023 | 460.09 Mn |
| Jun 30, 2023 | 430.77 Mn |
| Mar 31, 2023 | 399.71 Mn |
| Dec 31, 2022 | 286.45 Mn |
| Sep 30, 2022 | 203.34 Mn |
| Jun 30, 2022 | 249.84 Mn |
| Mar 31, 2022 | 190.03 Mn |